Annexin A2 Expression in the Aerogenous Spread of Pulmonary Invasive Mucinous Adenocarcinoma with Gastric Lineage.
Journal
Case reports in oncological medicine
ISSN: 2090-6706
Titre abrégé: Case Rep Oncol Med
Pays: United States
ID NLM: 101581035
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
09
2019
revised:
08
05
2020
accepted:
08
05
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Spread through air spaces (STAS) is a unique form of lung cancer progression associated with a worse prognosis. However, the mechanisms underlying STAS and the associated proteins remain unclear. Annexin A2 (ANX A2), which is a membrane-binding protein involved in cell adhesion, is known to promote cancer invasion. In this report, we describe the immunohistochemical analysis of ANX A2 expression in an invasive mucinous adenocarcinoma (IMAC) resected from a 63-year-old man in whom the tumor cells had detached from the alveolar wall and exhibited STAS. At the detachment site, we observed cytoplasmic ANX A2 positivity on the basal side and in the exfoliative gap, as well as reduced collagen IV positivity expression. This biomarker pattern suggested an IMAC with gastric lineage. We hypothesize that ANX A2 is secreted from the basal sides of tumor cells and induces tumor cell detachment by degrading the basement membrane. A further comparison of this case with an IMAC with nongastric lineage suggested the following probabilities: (1) ANX A2 likely contributes to STAS in a manner that is dependent on its subcellular localization. (2) Both the subcellular localization of ANX A2 and the detachment site depend on tumor cell characteristics, including the biomarker immunophenotype.
Identifiants
pubmed: 32509366
doi: 10.1155/2020/2492636
pmc: PMC7254091
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2492636Informations de copyright
Copyright © 2020 Kazumori Arai et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding the publication of this article.
Références
Transl Res. 2015 Aug;166(2):196-206
pubmed: 25795236
Clin Cancer Res. 2007 Jun 15;13(12):3518-27
pubmed: 17575214
Case Rep Oncol Med. 2019 Aug 7;2019:5064852
pubmed: 31485361
Ann Thorac Surg. 2019 Sep;108(3):945-954
pubmed: 30914285
Am J Clin Pathol. 2001 Jan;115(1):69-79
pubmed: 11190809
Am J Surg Pathol. 1992 Jul;16(7):675-86
pubmed: 1326898
Thorac Cancer. 2019 Feb;10(2):256-267
pubmed: 30605235
Int J Oncol. 2018 Jan;52(1):5-18
pubmed: 29115416
Mod Pathol. 2008 Aug;21(8):992-1001
pubmed: 18516041
J Exp Clin Cancer Res. 2010 May 23;29:53
pubmed: 20492722
Transl Lung Cancer Res. 2017 Oct;6(5):508-512
pubmed: 29114467
Eur Respir J. 2012 Jun;39(6):1437-42
pubmed: 22075483
Lung Cancer. 2018 Sep;123:107-111
pubmed: 30089579
Am J Clin Pathol. 1998 Apr;109(4):423-30
pubmed: 9535396
Cancer Microenviron. 2011 Aug;4(2):199-208
pubmed: 21909879
Thorac Cancer. 2017 Nov;8(6):710-713
pubmed: 28851076
World J Gastrointest Oncol. 2014 Sep 15;6(9):311-24
pubmed: 25232456
Oncol Lett. 2017 Sep;14(3):3701-3704
pubmed: 28927134
J Thorac Oncol. 2019 Jan;14(1):87-98
pubmed: 30244070
Am J Surg Pathol. 2019 Aug;43(8):1033-1041
pubmed: 31107717
Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2515-2529
pubmed: 28867585
Onco Targets Ther. 2016 Dec 28;10:153-163
pubmed: 28096683
J Cell Commun Signal. 2014 Jun;8(2):125-33
pubmed: 24838661
J Pathol Clin Res. 2017 Mar 22;3(2):139-152
pubmed: 28451462
J Thorac Oncol. 2015 May;10(5):806-814
pubmed: 25629637
Am J Pathol. 1993 May;142(5):1622-30
pubmed: 8494054
J Thorac Oncol. 2011 Jan;6(1):209-17
pubmed: 21107292
Clin Transl Oncol. 2013 Nov;15(11):938-46
pubmed: 23529818
AJR Am J Roentgenol. 2014 Dec;203(6):W570-82
pubmed: 25415722
Int J Cancer. 2005 Oct 10;116(6):876-84
pubmed: 15856467
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Mol Cancer Res. 2017 Jan;15(1):93-105
pubmed: 27760843